STOCK TITAN

Kazia Therapeutics Limited American Depositary Shares - $KZIA STOCK NEWS

Welcome to our dedicated news page for Kazia Therapeutics American Depositary Shares (Ticker: $KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kazia Therapeutics American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kazia Therapeutics American Depositary Shares's position in the market.

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) announces positive preliminary results from a combination therapy trial for diffuse midline gliomas (DMGs) at the Society of Neuro-Oncology 2023 Annual Meeting. The trial, PNOC022, has shown a median overall survival (OS) of 16.5 months, significantly higher than the standard of care. The study has enrolled 68 patients and has partnered with 29 leading children's cancer centers globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
-
Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announces promising preclinical data for paxalisib in the treatment of metastatic melanoma, indicating potential as a therapeutic strategy for BRAF-mutant cutaneous melanoma. The data, published in Molecular Cancer Therapeutics, demonstrates paxalisib's inhibition of melanoma cell growth and positive effects on overall survival in preclinical models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kazia Therapeutics provides a preliminary update on the Phase 2 clinical trial evaluating paxalisib as a monotherapy treatment for relapsed/refractory primary central nervous system lymphoma (r/r PCNSL). The study aims to assess the efficacy and safety of paxalisib in up to 25 patients based on objective response rate, duration of response, progression-free survival, and overall survival. So far, 14 patients have been enrolled, and early clinical activity has been observed. However, some patients experienced treatment-related adverse events, leading to dose reductions and early termination. The protocol is being optimized to improve tolerability and durability of response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
Rhea-AI Summary
Kazia Therapeutics presents selected clinical data from Phase 1 trial of EVT801 at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
-
Rhea-AI Summary
Kazia Therapeutics announces intention to de-list from ASX
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.79%
Tags
none
-
Rhea-AI Summary
Kazia Therapeutics provides update on upcoming data presentations at international scientific meetings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Rhea-AI Summary
Kazia Therapeutics' data from Phase II study of paxalisib selected for oral presentation at SNO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
Kazia Therapeutics' lead program, paxalisib, has been granted Fast Track Designation (FTD) by the FDA for the treatment of brain metastases. All patients in the ongoing Phase 1 clinical trial responded positively to the combination of paxalisib with radiotherapy. Brain metastases are a common complication of many tumors and survival rates are generally low. Paxalisib is also being studied in other clinical trials for glioblastoma and pediatric patients with diffuse midline gliomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
Kazia Therapeutics Limited American Depositary Shares

Nasdaq:KZIA

KZIA Rankings

KZIA Stock Data

7.45M
219.00M
18.54%
0.98%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW SOUTH WALES 2113

About KZIA

innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi